New York State Common Retirement Fund boosted its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 1.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 436,799 shares of the biotechnology company’s stock after purchasing an additional 4,281 shares during […]
Repligen (NASDAQ:RGEN – Get Free Report) had its price target dropped by investment analysts at UBS Group from $210.00 to $170.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. UBS Group’s target price suggests a potential upside of 24.51% from the stock’s […]
Repligen Co. (NASDAQ:RGEN – Free Report) – Stock analysts at Zacks Research decreased their Q3 2023 EPS estimates for shares of Repligen in a note issued to investors on Thursday, October 26th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will earn $0.18 per share for the quarter, down from their prior […]
Repligen (NASDAQ:RGEN – Free Report) had its price target cut by JPMorgan Chase & Co. from $200.00 to $180.00 in a research note released on Tuesday morning, Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. Several other equities analysts have also recently weighed in on RGEN. Stephens lifted their target […]
Geneva Capital Management LLC decreased its position in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 5.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 123,606 shares of the biotechnology company’s stock after selling 6,547 shares during the period. Geneva Capital Management LLC’s holdings in Repligen […]